Ziv et.al. studied the adverse events in Infants with cCMV treated with valganciclovir for a period of one year. They concluded that even though valganciclovir treatment is safe but a close monitoring of white blood cell count and hemoglobin levels is advisable. Amongst all, drug induced anemia should be a primary concern.
The Pediatric Infectious Disease Journal